Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser.
Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
www.ahrq.gov

Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

Part 3. Imatinib for Chronic Myeloid Leukemia (CML)

Technology Assessment


The technology assessment program at the Agency for Healthcare Research and Quality (AHRQ) provides technology assessments for the Centers for Medicare & Medicaid Services (CMS). These technology assessments are used by CMS to inform its national coverage decisions for the Medicare program as well as provide information to Medicare carriers.

AHRQ's technology assessment program uses state-of-the-art methodologies for assessing the clinical utility of medical interventions. Technology assessments are based on a systematic review of the literature, along with appropriate qualitative and quantitative methods of synthesizing data from multiple studies.

Select for PDF Version (850 KB). PDF Help.



Contents

Introduction
Methods
Results
Discussion
References
Included Studies
Excluded Studies
Appendixes

Prepared for AHRQ under Contract No. 290-02-0025. By Amy P. Abernethy, M.D.; Douglas C. McCrory, M.D., M.H.S.; Duke Evidence-based Practice Center, Center for Clinical Health Policy Research.

Current as of November 2005


Internet Citation:

Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy. Part 3. Imatinib for Chronic Myeloid Leukemia (CML). Technology Assessment. November 2005. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/clinic/ta/cml/


 

AHRQ Advancing Excellence in Health Care